Abstracts tagged "DMARDs and tumor necrosis factor (TNF)"

Abstract Number: 1484 • 2019 ACR/ARP Annual Meeting
The Impact of Time Since First Diagnosis on the Efficacy and Safety of Tofacitinib in Patients with Active Psoriatic Arthritis
Peter Nash¹, Maria Greenwald ², Liang-Hung Lin ³, Wei Yu ⁴, Paul Santos Estrella ⁵, Rajiv Mundayat ⁶, Daniela Graham ⁷ and Douglas Veale ⁸, ¹University of Queensland, Brisbane, Queensland, Australia, ²Desert Medical Advances, Palm Desert, CA, ³AIR, Taichung Tzu Chi Hospital, Taichung City, Taiwan (Republic of China), ⁴Pfizer Inc, Beijing, China (People's Republic), ⁵Pfizer Inc, Makati, Philippines, ⁶Pfizer Inc, New York, NY, ⁷Pfizer Inc, Groton, CT, ⁸EULAR Centre For Arthritis And Rheumatic Diseases and The Conway Institute, Dublin, Ireland
Background/Purpose: Early identification, diagnosis, and treatment of psoriatic arthritis (PsA) is important in preventing long-term joint damage and disability, and the associated socioeconomic consequences.1 Tofacitinib…
Abstract Number: 1550 • 2019 ACR/ARP Annual Meeting
Ixekizumab Demonstrates Consistent Improvement up to Week 108 in Psoriatic Arthritis Across Individual ACR Components for Patients Naïve to Biologic DMARDs or with Previous Inadequate Response to TNF Inhibitors
Anthony Turkiewicz¹, Aubrey Trevelin Sprabery ², Amanda Gellett ², So Young Park ² and Arnaud Constantin ³, ¹Rheumatology Associates, Birmingham, AL, ²Eli Lilly and Company, Indianapolis, IN, ³Hôpital Pierre-Paul Riquet, Toulouse, France
Background/Purpose: While the composite ACR core data set is considered a standard for assessing disease severity and improvement in PsA, understanding the response rates of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].